Please assess the completion status of the following clinical trial:

Trial Title: Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Considered healthy as per medical judgment of the investigator~2. Age: 20 to 45 years~3. Sex: Male, Female and Transgender~4. For married women, a negative urine pregnancy test (Rapid Diagnostic Test) during screening and prior to first, second and third dose of vaccination.Moreover, medical history will be taken thoroughly by study physician from the woman of childbearing age to completely exclude the probability of pregnancy.The women who are married and living with a partner must agree to use a reliable contraceptive method to prevent pregnancy until final follow-up following vaccination. However abstinence is also acceptable.~Exclusion Criteria:~1. Prior history of hepatitis B infection~2. Vaccination with any hepatitis B vaccine~3. Recent febrile illness (within 2 weeks)~4. Known or suspected hypersensitivity to any component of Hepatitis B vaccine (e.g., aluminium, yeast).~5. History of received hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product.~6. Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids) more than 14 days with in last 6 months. Does not include topical and inhaled steroids.~7. Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine.~8. Pregnant women, nursing mothers, and women planning to become pregnant within the study period.~9. HBsAg reactive, anti-HBs antibody (≥10mlU/ml), anti-HBc (total) reactive, and abnormal liver function test \[serum alanine aminotransferase (ALT) level\], serum creatinine and CBC (As mentioned in Appendix IV).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Hepa B (Type: EXPERIMENTAL): 79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
- Engerix B (Type: ACTIVE_COMPARATOR): 79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).